Ligandal utilizes artificial intelligence for precision targeting and delivery in therapeutics. The company offers AI-driven peptide design and a database of custom-designed targeting molecules.

Ligandal

Ligandal | 1,208 followers on LinkedIn. Ligandal is developing precision molecular therapeutics and targeted delivery technologies. | Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies.

Author, speaker, connector

Christine Peterson

Mark Young

Chief Innovation Officer @ Sama Therapeutics | AI & Data Science Advisor

Russell Hanson

Chairman & CEO @Ligandal, Biomaterials Scientist and Nanoengineer, Forbes 30Under30 in Healthcare

Andre Watson

Ligandal ’s CEO, Andre Watson, presented at the second annual Entrepreneurship, Longevity and Biotech conference at Florida Atlantic University - College of Business

HSTS

Content Delivery Network

jsDelivr

U.S. Server Location

HSTS IncludeSubdomains PreLoad

Cloudflare Bot Manager

Founder, Chairman & CEO

Sales and Support

Bryce Chaney

Executive Assistant to the CEO

Diana Douglas

Lacarya Scott

President & COO

Founder, CEO & Chairman

Christian Foster

Co-Founder & CTO

Northeastern US Seed Stage Companies With Less Than $10M in Revenue

Greater New York Area Companies With Less Than $10M in Revenue (Top 10K)

East Coast Seed Stage Companies With Less Than $1B in Revenue

Northeastern US Seed Stage Companies With Less Than $1M in Revenue

Ligandal's mission is to create precision delivery platform to cure and treat disease. We are driving the discovery and delivery of a broad array of gene therapies, genetic materials, and gene-specific payloads with unprecedented precision at the cellular and sub-cellular level. Our ligand discovery engine allows for rapid design of diagnostically-responsive materials, capable of shuttling a variety of nucleic acid and protein payloads (including CRISPR and mRNA) to specific cell types. We are initially applying this technology to indications in hematology, immuno-oncology, and infectious disease.

Seed Round - Ligandal

Angel Round - Ligandal

Convertible Note - Ligandal

Computer and Software Services and Scientific Services

Brooklyn

New York

United States

North America

Methods and compositions for nucleic acid and protein payload delivery

Ligandal Inc. Appoints Tushar Nuwal as Chief Operating Officer and Chief Business Officer

Methods and compositions for genome editing

Identification of biomimetic viral peptides and uses thereof

Methods and compositions for large-scale conjugatable polymer and protein …

Methods and compositions for diagnostically-responsive ligand-targeted delivery …

Ligandal Is Developing Potential Antidote And Vaccine To SARS-CoV-2

Ligandal develops systems for delivering antidotes, vaccines, gene therapies, and viral vectors to specific cells, tissues, or organs.

Ligandal's technology can target virtually any cellular receptor, enabling precise delivery of therapeutic agents.

Ligandal uses computational techniques to predict the behavior of their constructs before creating them.

Ligandal creates nanomaterials that utilize peptide targeting ligands to deliver CRISPR and other genetic materials into specific cells.

Ligandal is developing technologies aimed at defending against pandemics, including treatments and vaccines for COVID-19.

HTML5

Google Analytics

Google Fonts

Square E-Commerce (formerly Weebly)

jQuery

DigiCert

Adobe Fonts

Apache Server

Google Compute Engine

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 19, 2024 2:34 PM	1ce81764
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 2:34 PM	327a22fd
crunchbase trigger	general	Nov 19, 2024 2:34 PM	1e01aa88
crunchbase profile	general	Nov 20, 2024 4:49 AM	79db6f4d
li profile	general	Nov 19, 2024 2:34 PM	c9db6f3a
translate crunchbase fundingrounds	general	Nov 20, 2024 5:35 AM	609138a7
peers	general	Nov 19, 2024 2:34 PM	e3a5ce9c
news basic	general	Nov 19, 2024 2:34 PM	1ef8d25b
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

LIGA

COM:LIGANDAL

Ligandal